ANGO News and Press, AngioDynamics Inc. From 03/13/23

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial re...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and ...

Summary Merit Medical delivered a modestly better than expected fourth quarter, with a little upside on revenue and a $0.02/share beat at the operating income line. Procedure normalization in areas like cardiology and electrophysiology should pull Merit along toward improved volumes in ...

The healthcare sector spans a number of intriguing areas for investors. These include pharmaceuticals, health insurance, and medical devices. Within that last group sits AngioDynamics (NASDAQ: ANGO) , a little-known company that makes devices for treating peripheral vascular disease. ...

Summary AngioDynamics posted a pretty clean fiscal second quarter that was a little better than the sell-side expected, and that seemed to drive a meaningful relief rally for the beaten-down shares. Lackluster results from AngioVac/AlphaVac bear watching, given that they're important gr...

The following slide deck was published by AngioDynamics, Inc. in conjunction with their 2023 Q2 earnings call. For further details see: AngioDynamics, Inc. 2023 Q2 - Results - Earnings Call Presentation

AngioDynamics, Inc. (ANGO) Q2 2023 Earnings Conference Call January 05, 2023, 08:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - Executive Vice President and CFO Conference Call Participants Jayson Bedford - Raymond James Bi...

AngioDynamics press release ( NASDAQ: ANGO ): Q2 Non-GAAP EPS of $0.01 beats by $0.02 . Revenue of $85.4M (+9.1% Y/Y) beats by $1.02M . Fiscal Year 2023 Financial Guidance: Management is reaffirming its previously issued fiscal year 2023 guidance. Management expe...

Fiscal Year 2023 Second Quarter Highlights Net sales of $85.4 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $24.5 million increased 29.7% Med Device net sales of $60.9 million increased 2.6% Gross margin of 52.8% increased ...

As painful as market volatility can be, investors can leverage this to their advantage. The Nasdaq Composite is loaded with growth-oriented stocks. And while this has been a good place to be for the last decade-plus, growth stocks have had no place to hide in 2022 with surging interest rates ...